Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
FP05 - Mesothelioma, Thymoma and Other Thoracic Malignancies
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Mesothelioma, Thymoma and Other Thoracic Malignancies
-
+
FP05.01 - Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Choice of Second-line Therapy
00:00 - 00:00 | Presenter: Kathleen Claire Kerrigan
- Abstract
Loading...
-
+
FP07 - Pathology
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
-
+
FP07.17 - The Impact of Blood Based Host Immune Profile to Identify Aggressive Early Stage NSCLC
00:00 - 00:00 | Presenter: Eric Schaefer
- Abstract
Loading...
-
+
P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
P01.07 - Real World Outcomes of Advanced Non-Small Cell Lung Cancer (NSCLC) With Attention to Carboplatin Area Under the Curve (AUC) = 5 Versus 6
00:00 - 00:00 | Presenter: Lindsey Fitzgerald
- Abstract
Loading...
-
+
P15 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Novel Immunotherapeutics (Phase I)
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P15.02 - Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCLC
00:00 - 00:00 | Presenter: Sonam Puri
- Abstract
Loading...
-
+
P89 - Targeted Therapy - Clinically Focused - Translational
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P89.05 - Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis
00:00 - 00:00 | Presenter: Kathleen Claire Kerrigan
- Abstract
Loading...
-
+
OA09 - Mesothelioma from Pathogenesis to Therapy
- 15:30 - 16:30
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Mesothelioma, Thymoma and Other Thoracic Malignancies
-
+
OA09.05 - Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician’s Choice of First-line Platinum Chemotherapy
15:50 - 16:00 | Presenter: Kathleen Claire Kerrigan
- Abstract
Loading...
-
+
MA08 - Advances in Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non Small Cell Lung Carcinoma
- 16:45 - 17:45
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
-
+
MA08.03 - Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling
16:45 - 16:50 | Presenter: Wallace Akerley
- Abstract
Loading...